New collaboration to evaluate the potential of bacterial antigens that mimic tumor antigens and neoantigens ("onco-mimics") to drive immune responses.

Funds will be used to advance Axial’s gut-targeted programs in Parkinson’s Disease and Autism Spectrum Disorder. Seventure Partners commits new funding from...

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...

Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C

Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

The latest investment will help drive expansion and accelerate research & development to introduce new and novel ingredients to the market.

The $30 million in new investment will fuel expansion and accelerate R&D project execution. This funding round opens up an opportunity to explore different ways to meet...

A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors. His experience of successfully managing several...

Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...